Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- Check5 days agoChange DetectedRevision updated to v3.4.3. The previous revision v3.4.2 has been superseded.SummaryDifference0.1%

- Check12 days agoChange DetectedNo substantive content additions or deletions were detected; the study details, eligibility criteria, and outcome measures remain unchanged.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision indicator updated to v3.4.2 and the government funding status notice (including the prior Revision: v3.4.1) was removed; no study content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a notice about a lapse in government funding and that the NIH Clinical Center is open, with status updates linked to opm.gov. Updated the page revision to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary display option. Updated metadata items include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0, replacing Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page shows minor date-related updates to Study Record Dates, with new entries for 2026-01-15 and 2025-12-23 and removal of earlier items like Last Update Posted and 2025-06. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.